Literature DB >> 12212979

Side-effects of antituberculosis drug treatment in patients with chronic renal failure.

S J Quantrill1, M A Woodhead, C E Bell, C C Hardy, A J Hutchison, R Gokal.   

Abstract

Patients with chronic renal failure (CRF) have a high incidence of tuberculosis (TB). Those from the Indian subcontinent are at particular risk. The frequency of side-effects associated with antituberculous treatment in a group of patients with CRF was studied. All cases of TB in patients with CRF occurring over a 13-yr period at the Manchester Royal Infirmary, from 1986-1999, were identified by diagnostic coding, microbiology records and a TB database. The case notes were then reviewed. Twenty-four cases were identified, eight predialysis and 16 requiring regular dialysis. TB occurring in the dialysis group was extrapulmonary in every case. Nineteen of 24 (79%) patients were of Indian subcontinent origin and 14 of 16 (87%) dialysis patients were non-Caucasian. Adverse effects of treatment occurred in two of eight (25%) in the predialysis group and nine of 16 (56%) of the dialysis group. These were most commonly neuropsychiatric (6), hepatic (4) and gastrointestinal (4). Neuropsychiatric symptoms occurred exclusively in dialysis patients. In conclusion, a high incidence of side-effects from antituberculous medication, especially neuropsychiatric, hepatic and gastrointestinal, was identified in patients with chronic renal failure. Careful monitoring for side-effects is essential in this group, and consideration should be given to administering antituberculous chemoprophylaxis to all high-risk groups.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12212979     DOI: 10.1183/09031936.02.00298002

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Hepatotoxicity from antituberculous therapy in the elderly: a systematic review.

Authors:  Jennifer D Hosford; Michael E von Fricken; Michael Lauzardo; Myron Chang; Yunfeng Dai; Jennifer A Lyon; John Shuster; Kevin P Fennelly
Journal:  Tuberculosis (Edinb)       Date:  2014-12-18       Impact factor: 3.131

2.  Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions.

Authors:  Abdurrahman M Hamadah; Lynn M Beaulieu; John W Wilson; Timothy R Aksamit; James R Gregoire; Amy W Williams; John J Dillon; Robert C Albright; Macaulay Onuigbo; Venkateshwaran K Iyer; LaTonya J Hickson
Journal:  Nephron       Date:  2016-02-10       Impact factor: 2.847

3.  Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  Meijun Si; Huiqun Li; Yanru Chen; Hui Peng
Journal:  BMJ Case Rep       Date:  2018-05-18

4.  Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients.

Authors:  Aliasghar Farazi; Masoomeh Sofian; Mansoureh Jabbariasl; Sara Keshavarz
Journal:  Tuberc Res Treat       Date:  2014-11-24

5.  Encephalopathy secondary to isoniazid in patients on hemodialysis.

Authors:  M T Abbas; F Y Khan; S Sulimon; A Baidaa
Journal:  Indian J Nephrol       Date:  2013-01

6.  End-stage Renal Disease and Risk of Active Tuberculosis: a Nationwide Population-Based Cohort Study.

Authors:  Jinsoo Min; Soon Kil Kwon; Hye Won Jeong; Joung-Ho Han; Yeonkook Joseph Kim; Minseok Kang; Gilwon Kang
Journal:  J Korean Med Sci       Date:  2018-12-13       Impact factor: 2.153

7.  Intestinal tuberculosis in a patient with end-stage renal disease on hemodialysis: A case report.

Authors:  In Hee Lee; Seong Gyu Kim; Joong Goo Kwon; Chun-Seok Yang; Sungmin Kang; Min-Kyung Kim; Dong Jik Ahn
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.